Long-term efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) once weekly versus placebo in participants with obesity

Obesity is a chronic condition that increases the risk of type 2 diabetes, high blood pressure, and heart disease, and a clinical trial is now testing whether a weekly injection combining two drugs—cagrilintide and semaglutide (CagriSema)—can help people lose more weight than placebo. Diet and exercise alone do not work for everyone with obesity, and existing medications have limited long-term effectiveness. This study addresses whether a dual-action drug can produce greater weight loss and whether that loss can be maintained on a lower dose. If CagriSema proves safe and effective, it could become a new treatment option for obesity—a condition that affects millions in the UK and strains the NHS through related illnesses like diabetes and cardiovascular disease. The trial also tests whether lower maintenance doses can sustain weight loss, which could reduce side effects and treatment costs. All participants receive diet and exercise counselling, so the results will show the drug’s effect on top of lifestyle changes—the real-world scenario for most patients.